<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01736033</url>
  </required_header>
  <id_info>
    <org_study_id>TMS1011</org_study_id>
    <nct_id>NCT01736033</nct_id>
  </id_info>
  <brief_title>Advanced Benefits of Alpha-blocker Monotherapy on Lower Urinary Tracts Symptoms(LUTS) Patients</brief_title>
  <acronym>ABSOLUTE</acronym>
  <official_title>A Multicenter, Randomized, Double-blind, Clinical Study to Investigate the Efficacy and Safety of Treatment With Tamsulosin 0.2mg Mono and Tamsulosin 0.2mg, Finasteride 5mg Combination Therapy in Patients With LUTS/BPH</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Korea, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical Research Collaborating Center, Seoul, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the clinical efficacy of alpha-blocker monotherapy
      and alpha-blocker + 5-alpha reductase inhibitor combination therapy in benign prostate
      hyperplasia patients, and suggest guidelines of the combination therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Even though it should be decided on patients cautiously under careful consideration about
      prostate volume, Prostate Specific Antigen(PSA) level, symptom score and maximum uroflow,
      recently the combination therapy of alpha-blocker and 5-alpha reductase inhibitor has been
      tried imprudently in Korea.

      As a result of several clinical trials which had conducted overseas for releasing the
      combination drug of alpha-blocker and 5-alpha reductase inhibitor, the superiority of the
      combination therapy has been proved, however, plenty of patients still don't derive
      additional profit from it.

      Therefore, in this study, the investigators anticipate to meet with meaningful results on the
      clinical efficacy of alpha-blocker monotherapy and alpha-blocker + 5-alpha reductase
      inhibitor combination therapy in Korean benign prostate hyperplasia patients, and provide
      guidelines of the combination therapy.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Progression</measure>
    <time_frame>1 &amp; 2 months after baseline, and then every 3 months up to 4 years</time_frame>
    <description>One of below
Deterioration of the symptoms
Acute urinary retention
Renal failure
Recurrent urinary tract infection
Urinary incontinence
Surgical procedure related to benign prostate hyperplasia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>International Prostate Symptom Score(IPSS)</measure>
    <time_frame>1 &amp; 2 months after baseline, and then every 3 months up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Consultation on Incontinence Modular Questionnaire(ICIQ) male LUTS-short form</measure>
    <time_frame>every 6 months up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uroflowmetry</measure>
    <time_frame>every 6 months up to 4 years</time_frame>
    <description>including Qmax, voided volume and post-void residual volume(PVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate volume</measure>
    <time_frame>every 1 year up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Response Assessment(GRA)</measure>
    <time_frame>every 1 year up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA level</measure>
    <time_frame>every 1 year up to 4 years</time_frame>
    <description>PSA level will be examined in the central laboratory and be reported to each center as an adjusted number. It is because PSA level tends to decrease to 50% of baseline after taking finasteride for 1~4 years, so there is possibilities that the blindedness is broken with the actual result.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Chemistry</measure>
    <time_frame>every 1 year up to 4 years</time_frame>
    <description>including Sodium, Potassium, Glucose, Urea nitrogen, Creatinine, ASpartate Transaminase(AST), ALanine Transaminase(ALT), Total bilirubin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>every visit up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examination</measure>
    <time_frame>every 1 year up to 4 years</time_frame>
    <description>Digital Rectal Exam, Breast exam</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Male Sexual Health Questionnaire</measure>
    <time_frame>every 6 months up to 4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">545</enrollment>
  <condition>Benign Prostate Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Tamsulosin + Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Tamsulosin 0.2mg + Placebo 5 mg daily until clinical progression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tamsulosin + Finasteride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tamsulosin 0.2mg + Finasteride 5 mg daily until clinical progression</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamsulosin</intervention_name>
    <description>1 tablet(0.2mg) orally q.d.</description>
    <arm_group_label>Tamsulosin + Placebo</arm_group_label>
    <arm_group_label>Tamsulosin + Finasteride</arm_group_label>
    <other_name>Harnal D (brand name in Asia)</other_name>
    <other_name>Flomax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Finasteride</intervention_name>
    <description>1 tablet(5mg) orally q.d.</description>
    <arm_group_label>Tamsulosin + Finasteride</arm_group_label>
    <other_name>Proscar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 tablet(0.2mg) orally q.d.</description>
    <arm_group_label>Tamsulosin + Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male patients aged over 50

          -  Clinically diagnosed benign prostate hyperplasia(BPH)

          -  8 ≤ IPSS ≤ 30

          -  4 ml/sec ≤ Q max ≤ 15 ml/sec

          -  minimum voided volume ≥ 125 ml

          -  Post voided residual volume ≤ 250

          -  Volunteer who singed on informed consent documents

        Exclusion Criteria:

          -  Past history of surgical procedure experience related to BPH

          -  Past history of taking 5-alpha reductase inhibitor(5-ARI) within 6 months before
             screening, or for more than 12 months regardless of the point of time

          -  Past history of taking alpha blocker within 2 weeks before screening

          -  Past history of acute urinary retention within 3 months before screening

          -  Serum PSA ≥ 10 ng/ml (but, in the case of 4 ng/ml ≤ PSA &lt; 10 ng/ml, the patients can
             be included only if prostate cancer is excluded by prostate biopsy)

          -  Anatomical abnormalities of lower urinary tracts(urethrostenosis, diverticulosis,
             bladder neck contracture)

          -  Clinical status that affects voiding other than BPH(neurogenic bladder, Chronic
             Prostatitis/Chronic Pelvic Pain Syndrome, urinary infection, etc.)

          -  Unstable and significant medical condition including below

               -  Unstable angina pectoris, myocardial infarction, cerebrovascular disease within 6
                  months before screening

               -  Past history of malignant tumor including skin basal cell carcinoma within 5
                  years before screening

               -  Medically uncontrollable diabetes mellitus, peptic ulcer disease

               -  Severe hepatic diseases

               -  Past history of renal failure or renal disease (serum creatinine &gt; 1.4mg/dl)

               -  Condition expected serious adverse event due to the investigational drug

          -  Other conditions considered not eligible for the trial upon investigator's judgement
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Soo Woong Kim, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chungbuk National University Hospital</name>
      <address>
        <city>Cheongju</city>
        <state>Chungbuk</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soon Chun Hyang University Hospital Cheonan</name>
      <address>
        <city>Cheonan</city>
        <state>Chungnam</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University Sacred Heart Hospital</name>
      <address>
        <city>Anyang</city>
        <state>Gyeoggi</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bucheon St. Mary's Hospital</name>
      <address>
        <city>Bucheon</city>
        <state>Gyeonggi</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soon Chun Hyang University Hospital Bucheon</name>
      <address>
        <city>Bucheon</city>
        <state>Gyeonggi</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Gyeonggi</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <state>Gyeonggi</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Hwasun</city>
        <state>Jeonnam</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eulji General Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Shapiro E, Lepor H. Pathophysiology of clinical benign prostatic hyperplasia. Urol Clin North Am. 1995 May;22(2):285-90.</citation>
    <PMID>7539174</PMID>
  </reference>
  <reference>
    <citation>Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet. 1991 Aug 24;338(8765):469-71.</citation>
    <PMID>1714529</PMID>
  </reference>
  <reference>
    <citation>Bosch JL, Kranse R, van Mastrigt R, Schröder FH. Reasons for the weak correlation between prostate volume and urethral resistance parameters in patients with prostatism. J Urol. 1995 Mar;153(3 Pt 1):689-93.</citation>
    <PMID>7532234</PMID>
  </reference>
  <reference>
    <citation>Chung TG, Chung J, Lee MS, Ahn H. Prevalence of benign prostatic hyperplasia in Jeong-Eup Area: community-based study. Korean J Urol 1999;40:52-8.</citation>
  </reference>
  <reference>
    <citation>The prevalence of benign prostatic hyperplasia in elderly men in Korea: a community-based study. Park HK, Park H, Cho S, Bae J, Jeong S, Hong SK, et al. Korean J Urol 2009;50:843-7.</citation>
  </reference>
  <reference>
    <citation>Lepor H, Gup DI, Baumann M, Shapiro E. Laboratory assessment of terazosin and alpha-1 blockade in prostatic hyperplasia. Urology. 1988 Dec;32(6 Suppl):21-6.</citation>
    <PMID>2462301</PMID>
  </reference>
  <reference>
    <citation>Noble AJ, Chess-Williams R, Couldwell C, Furukawa K, Uchyiuma T, Korstanje C, Chapple CR. The effects of tamsulosin, a high affinity antagonist at functional alpha 1A- and alpha 1D-adrenoceptor subtypes. Br J Pharmacol. 1997 Jan;120(2):231-8.</citation>
    <PMID>9117115</PMID>
  </reference>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2012</study_first_submitted>
  <study_first_submitted_qc>November 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2012</study_first_posted>
  <last_update_submitted>May 13, 2014</last_update_submitted>
  <last_update_submitted_qc>May 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Soo Woong Kim, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Lower Urinary Tracts Symptoms</keyword>
  <keyword>5 alpha reductase inhibitor</keyword>
  <keyword>Proscar</keyword>
  <keyword>Finasteride</keyword>
  <keyword>alpha blocker</keyword>
  <keyword>Tamsulosin</keyword>
  <keyword>Harnal D</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Lower Urinary Tract Symptoms</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamsulosin</mesh_term>
    <mesh_term>Finasteride</mesh_term>
    <mesh_term>Adrenergic alpha-Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

